Know Cancer

or
forgot password

Phase I / II Study of the Combination of Doxycycline With Temozolomide and Ipilimumab in Patients With Metastatic Melanoma


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Melanoma

Thank you

Trial Information

Phase I / II Study of the Combination of Doxycycline With Temozolomide and Ipilimumab in Patients With Metastatic Melanoma


Study Groups:

If you are found to be eligible to take part in this study, you will be assigned to a study
group based on when you join this study. Up to 5 groups of 3-6 participants will be
enrolled in the Phase I portion of the study, and up to 28 participants will be enrolled in
Phase II.

If you are enrolled in the Phase I portion, the dose of doxycycline you receive will depend
on when you joined this study. The first group of participants will receive the lowest dose
level of doxycycline. Each new group will receive a higher dose of doxycycline than the
group before it, if no intolerable side effects were seen. This will continue until the
highest tolerable dose of doxycycline is found.

If you are enrolled in the Phase II portion, you will receive doxycycline at the highest or
most clinically active dose that was tolerated in the Phase I portion.

All participants will receive the same dose level of temozolomide and ipilimumab.

Study Drug Administration:

You will start taking doxycycline on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1
starts) by mouth 2 times a day by itself for 1 week. You should fast (not eat or drink
anything but water) for at least 2 hours before and 1 hour after you take the study drug.

After that, on Day 1 of Cycle 1, you will start taking the combination of temozolomide and
ipilimumab. You will receive ipilimumab by vein over 90 minutes every 3 weeks.

On Day 1 of Cycle 1, you will start taking temozolomide by mouth with about 1 cup (8 ounces)
of water on Days 1-4 of each cycle. You should fast for at least 2 hours before and 2 hours
after you take the study drug.

You will continue taking doxycycline by mouth 2 times a day throughout the study.

Each study cycle is 3 weeks except the first cycle, which is 4 weeks. This is because it
includes 1 week of doxycycline given by itself.

You will be given a study drug diary to record the times and doses that you take the study
drugs. You should bring the diary to each study visit. You should also bring any leftover
study drug with you to each study visit.

Study visits:

At every study visit, you will be asked about any drugs you may be taking, how you are
feeling, and if you have had any side effects.

On Day -6 of Cycle 1:

- You will have a physical exam if not done in the past 8 days.

- Your weight and vital signs will be measured.

- Your performance status will be recorded.

- Blood (about 1 tablespoon) will be drawn for routine tests if this was not done in the
past 8 days.

- Blood (about 4 tablespoons) will be drawn for biomarker testing. Biomarkers are found
in the blood and tissue and may be related to your reaction to the study drugs.

- You will have a tumor biopsy performed to test if the tumor has the iNOS protein, which
is a target for doxycycline. To collect a tumor biopsy, the affected area is numbed
with anesthetic, and a small amount of tissue is withdrawn using a punch knife or
removed by a surgery.

On Day 1 of Cycles 1 and 2:

- You will have a physical exam, including measurement of your weight and vital signs.

- Your performance status will be recorded.

- Blood (about 5 tablespoons) will be drawn for routine tests and biomarker testing.

- You will have an ECG.

- On Day 1 of Cycle 1, if you are in Phase II of the study, you will have a tumor biopsy
performed to test if doxycycline is able to block the iNOS protein. This biopsy is
optional if you are in Phase I.

On Day 8 of Cycle 1, if you are in Phase I:

- Blood (about 5 tablespoons) will be drawn for routine tests and biomarker testing.

- Your vital signs will be measured.

- Your performance status will be recorded.

On Day 15 of Cycle 1, if you are in Phase I, blood (about 5 tablespoons) will be drawn for
routine tests and biomarker testing.

On Day 1 of Cycles 3 and beyond:

- You will have a physical exam, including measurement of your weight and vital signs.

- Your performance status will be recorded.

- Blood (about 1 tablespoon) will be drawn for routine tests.

Every 6 weeks (2 cycles), you will have a CT scan, an MRI scan, and/or a bone scan to check
the status of the disease.

Length of Treatment:

You may continue taking doxycycline for as long as the doctor thinks it is in your best
interest. You may continue receiving temozolomide and ipilimumab for up to 4 cycles.

You will no longer be able to take the study drugs if the disease gets worse, if you start
having other health problems, if intolerable side effects occur, or if you are unable to
follow study directions.

Your participation on the study will be over once you have completed the end-of-treatment
visit.

End-of-Treatment Visi:t

Within 4 weeks after your last dose of study drugs:

- You will have a physical exam, including measurement of your weight and vital signs.

- Your performance status will be recorded.

- Blood (about 5 tablespoons) will be drawn for routine tests and biomarker testing.

- You will have an ECG.

- You will have a tumor biopsy performed to test if there is any change in the level of
iNOS protein.

This is an investigational study. Temozolomide is FDA approved and commercially available
to treat advanced brain tumors. It is commonly used to treat advanced melanoma but is not
FDA approved for it. Ipilimumab is FDA approved and commercially available to treat
advanced melanoma. Doxycycline is FDA approved and commercially available to treat various
infections, but using it to treat cancer is investigational.

Up to 58 patients will take part in this study. All will be enrolled at MD Anderson.


Inclusion Criteria:



1. Patient must be age >/= 18 years.

2. Patients must have histologically or cytologically confirmed diagnosis of malignant
(unresectable Stage III or Stage IV) melanoma, not amenable to resection with
curative intent.

3. Patients must have metastatic melanoma which has >25% of melanoma cells stained
positive for iNOS expression by CLIA-certified immunohistochemistry assay. However,
in phase I portion of the study, the requirement of >25% of melanoma cells stained
positive for iNOS expression does not apply.

4. Patients must be at least 21 days since surgery, radiation therapy and 6 weeks after
immunotherapy with regimens including vaccines, interferon, IL-2, etc. and fully
recovered from adverse effects of these therapies.

5. Patients must have evaluable disease for response.

6. There is no limit on the number of prior therapies for Phase I portion. For Phase II
portion only, patients may have received less than or equal to 1 prior chemotherapy
regimen for metastatic melanoma. There is no limit on prior immunotherapies or kinase
inhibitors. Patients with prior ipilimumab therapy will be excluded during the phase
II portion.

7. Patient must have an ECOG performance status of 0 or1.

8. Patient must have adequate liver and renal function as documented by the following
laboratory test results within 14 days prior to starting therapy: • total bilirubin
less than or equal to 1.5 x upper limit of normal (ULN); • AST (SGOT) and ALT (SGPT)
less than or equal to 2.5 X ULN or less than or equal to 5 X ULN if liver metastasis
is present; • serum creatinine less than or equal to 1.2 X ULN

9. Patient must have adequate bone marrow function as documented by the following
laboratory test results within 14 days prior to starting therapy: • platelets greater
than 100,000/mm3; • absolute neutrophil count (ANC) greater than 1500/mm3; •
hemoglobin greater than 9.0 g/dL;

10. Patient must have completed any prior chemotherapy, immunotherapy, radiation therapy,
biological therapy, or other investigational cancer therapy at least 4 weeks prior to
starting the study drug(s) and must have recovered from all acute side effects (to
CTCAE less than Grade 1) prior to initiation of the study drug(s). Patients who were
receiving mitomycin C or nitrosoureas must be 6 weeks from the last administration of
chemotherapy. For a prior BRAF inhibitor, the washout period is 7 days.

11. Patient (man or woman) must agree to practice effective contraception during the
entire study period, unless documentation of infertility exists, and for at least 4
weeks after the last dose of the study drug(s).

12. Patient must be willing and able to sign the informed consent form.

13. Patient must be willing and able to self-administer orally and document all doses of
doxycycline ingested.

14. Patients must be willing to have iNOS expression assay test done on disease easily
amenable to biopsy or suitable tissue obtained within the last 3 months.

Exclusion Criteria:

1. Patients who have received doxycycline or other tetracycline-analogs within the 4
weeks prior to the first dose of the study drug.

2. For Phase II portion only, patients with a diagnosis of ocular melanoma will be
excluded.

3. Patients with an inability to swallow tablets or capsules.

4. Patients with a symptomatic malabsorptive disorder (eg, Crohn's Disease) or removal
of either the terminal ileus or more than 2/3 of the small intestine.

5. Patients with active brain metastases or primary central nervous system (CNS)
malignancies; patients with previously treated brain metastasis may be included,
provided that no requirement for steroids and no evidence of progression for greater
than or equal to 8 weeks after a local brain treatment.

6. Patients with an active second malignancy.

7. Patients who are pregnant or breastfeeding.

8. Patients with clinically significant illnesses which could compromise participation
in the study, including, but not limited to:uncontrolled diabetes;active or
uncontrolled infection; acute or chronic liver disease (i.e., hepatitis,
cirrhosis);confirmed diagnosis of HIV infection; or, uncontrolled hypertension,
symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction
within the past 6 months, or uncontrolled cardiac arrhythmia.

9. Patients with history of autoimmune disease.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Response Rate

Outcome Description:

Overall survival (OS) and time to progression (TTP) calculated using Kaplan-Meier method. Overall response rate at end of study also calculated. Response rate calculated using point estimate, together with 95% confidence interval (CI). Kaplan-Meier method used to estimate progression free survival (PFS) time. PFS defined as time interval between start of treatment to date of disease progression, or death. RECIST version 1.1 used to evaluate response rate.

Outcome Time Frame:

2 cycles

Safety Issue:

No

Principal Investigator

Kevin B. Kim, MD,BA

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

2011-1165

NCT ID:

NCT01590082

Start Date:

November 2012

Completion Date:

Related Keywords:

  • Melanoma
  • Melanoma
  • Metastatic Melanoma
  • Advanced melanoma
  • Doxycycline
  • Ipilimumab
  • Yervoy
  • MDX010
  • BMS-734016
  • Temozolomide
  • Temodar
  • Melanoma

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030